

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D

ARMSTRONG ERNEST  
Form SC 13D  
April 08, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3) \*

Cobalis Corp.

-----  
(Name of Issuer)  
Common Stock

-----  
(Title of Class of Securities)

19074Y 20 5

-----  
(CUSIP Number)

Chaslav Radovich, 2445 McCabe Way, Suite 150, Irvine, CA 92614  
(949) 757-0001

-----  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

March 31, 2005

-----  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 19074Y 20 5

-----	
	1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). ERNEST ARMSTRONG
-----	
	2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b)
-----	
	3. SEC Use Only
-----	
	4. Source of Funds (See Instructions) 00
-----	
	5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
-----	
	6. Citizenship or Place of Organization U.S.
-----	
Number of	7. Sole Voting Power 113,055
Shares	-----
Beneficially	8. Shared Voting Power 2,000,000
Owned by	-----
Each	9. Sole Dispositive Power 113,055
Reporting	-----
Person	10. Shared Dispositive Power 2,000,000
With	-----
-----	
	11. Aggregate Amount Beneficially Owned by Each Reporting Person 2,113,055
-----	
	12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
-----	
	13. Percent of Class Represented by Amount in Row (11) 8.6%
-----	
	14. Type of Reporting Person (See Instructions) IN
-----	

# Edgar Filing: ARMSTRONG ERNEST - Form SC 13D

## ITEM 1. SECURITY AND ISSUER

-----

This statement relates to shares of the common stock, \$.001 par value of Cobalis Corp., a Nevada corporation (the "Issuer"). The principal executive offices of the Issuer are located at 2445 McCabe Way, Suite 150, Irvine, CA 92614.

## ITEM 2. IDENTITY AND BACKGROUND

-----

- (a) Name: Ernest Armstrong
- (b) Business Address: 2445 McCabe Way, Suite 150,  
Irvine, CA 92614
- (c) Present Principal Occupation: Vice President of the Issuer.
- (d) Disclosure of Criminal Proceedings: none
- (e) Disclosure of Civil Proceedings: none
- (f) Citizenship: U.S.

## ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

-----

Mr. Armstrong purchased 500 shares of the Issuer's common stock on March 30, 2005 for \$0.62 per share; this purchase was made using Mr. Armstrong's personal funds. Mr. Armstrong purchased 250 shares of the Issuer's common stock on March 31, 2005 for \$0.60 per share; this purchase was made using Mr. Armstrong's personal funds. On April 1, 2005, Mr. Armstrong acquired 12,056 shares of the Issuer's shares from Gene Pharmaceuticals, LLC in exchange for canceling a debt owed to him by Gene Pharmaceuticals, LLC. On April 7, 2005, Mr. Armstrong purchased 250 shares for \$0.589 per share using his personal funds. These transactions result in Mr. Armstrong owning 113,055 shares of the Issuer's common stock directly and personally, and having control of 2,000,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

## ITEM 4. PURPOSE OF TRANSACTION

-----

Mr. Armstrong purchased 500 shares of the Issuer's common stock on March 30, 2005 and 250 shares on March 31, 2005 to express his personal commitment to the Issuer. On April 1, 2005, Mr. Armstrong acquired 12,056 shares of the Issuer's shares from Gene Pharmaceuticals, LLC in exchange for canceling a debt owed to him by Gene Pharmaceuticals, LLC. On April 7, 2005, Mr. Armstrong purchased 250 shares of the Issuer's common stock for \$0.589 per share; this purchase was made using Mr. Armstrong's personal funds and to express his personal commitment to the Issuer. These transactions result in Mr. Armstrong owning 113,055 shares of the Issuer's common stock directly and personally, and having control of 2,000,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

## ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

-----

Mr. Armstrong beneficially owns a total of 2,113,055 shares of the Issuer's common stock as follows:

- (a) Ernest Armstrong, sole officer and director of the Issuer, owns 113,055

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D

shares individually, which comprises 0.5% of the Issuer's outstanding common stock, and 2,000,000 shares as sole owner of Gene Pharmaceuticals, LLC. Gene Pharmaceuticals, LLC directly owns 2,000,000 shares of the Issuer's common stock which comprises 8.1% of the Issuer's total issued and outstanding shares.

(b) Ernest Armstrong has sole voting and dispositive power as to the 113,055 shares he owns individually and as to the 2,000,000 shares which he controls as managing member and majority owner of Gene Pharmaceuticals, LLC.

(c) Mr. Armstrong purchased 500 shares of the Issuer's common stock on March 30, 2005 for \$0.62 per share; this purchase was made using Mr. Armstrong's personal funds. Mr. Armstrong purchased 250 shares of the Issuer's common stock on March 31, 2005 for \$0.60 per share; this purchase was made using Mr. Armstrong's personal funds. On April 1, 2005, Mr. Armstrong acquired 12,056 shares of the Issuer's shares from Gene Pharmaceuticals, LLC in exchange for canceling a debt owed to him by Gene Pharmaceuticals, LLC. Mr. Armstrong purchased 250 shares of the Issuer's common stock on April 7, 2005 for \$0.589 per share. These transactions result in Mr. Armstrong owning 113,055 shares of the Issuer's common stock directly and personally, and having control of 2,000,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

(d) Not Applicable.

(e) Not Applicable.

ITEM 6. CONTACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

-----  
None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

-----  
None.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

April 7, 2005

Date

/s/ Ernest Armstrong

-----  
Ernest Armstrong

The original statement shall be signed by each person on whose behalf the

## Edgar Filing: ARMSTRONG ERNEST - Form SC 13D

statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)